● Recruiting

Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma

Condition: Mantle Cell Lymphoma (MCL) · Sponsor: Sun Yat-sen University

PhasePhase 2

Planned participants50

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a single- arm, open-label, multicenter, phase II study to evaluate Acalabrutinib plus Rituximab for the treatment of elderly or low- to intermediate-risk younger untreated mantle cell lymphoma

This description comes directly from the study's public registry record.

Talk to the study team

Qingqing Cai · 02087342823 · caiqq@sysucc.org.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Sun yat-sen university cancer center, Sun yat-sen university

Guangzhou, Guangdong, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06846489